PT  - JOURNAL ARTICLE
AU  - Youngji Jo
AU  - Sydney Rosen
AU  - Karla Therese L Sy
AU  - Bevis Phiri
AU  - Amy N Huber
AU  - Muya Mwansa
AU  - Hilda Shakwelele
AU  - Prudence Haimbe
AU  - Mpande M Mwenechanya
AU  - Priscilla Lumano Mulenga
AU  - Brooke E Nichols
TI  - Changes in HIV Treatment Differentiated Care Utilization During the COVID-19 Pandemic in Zambia
AID  - 10.1101/2021.03.20.21254021
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.20.21254021
4099  - http://medrxiv.org/content/early/2021/03/22/2021.03.20.21254021.short
4100  - http://medrxiv.org/content/early/2021/03/22/2021.03.20.21254021.full
AB  - Background Differentiated service delivery (DSD) models aim to lessen the burden of HIV treatment on patients and providers in part by reducing requirements for facility visits and extending dispensing intervals. With the advent of the COVID-19 pandemic, minimizing patient contact with healthcare facilities and other patients, while maintaining treatment continuity and avoiding loss to care, has become more urgent, resulting in efforts to increase DSD uptake. We assessed the extent to which DSD coverage and antiretroviral treatment (ART) dispensing intervals have changed during the COVID-19 pandemic in Zambia.Methods We used patient data from Zambia’s electronic medical record system (SmartCare) for 737 health facilities, representing about 3/4 of all ART patients nationally, to compare the numbers and proportional distributions of patients enrolled in DSD models in the six months before and six months after the first case of COVID-19 was diagnosed in Zambia in March 2020. Segmented linear regression was used to determine whether the introduction of COVID-19 into Zambia further accelerated the increase in DSD scale-up.Results Between September 2019 and August 2020, 181,317 patients aged 15+ (81,520 and 99,797 from September 1, 2019 to March 1, 2020 and from March 1 to August 31, 2020, respectively) enrolled in DSD models in Zambia. Overall participation in all DSD models increased over the study period, but uptake varied by model. The rate of acceleration increased in the second period for home ART delivery (152%), ≤2-month fast-track (143%), and 3-month MMD (139%). There were significant decelerations in the increase in enrolment for 4-6-month fast-track (−28%) and ‘other’ models (−19%).Conclusions Participation in DSD models for stable ART patients in Zambia increased after the advent of COVID-19, but dispensing intervals diminished. Eliminating obstacles to longer dispensing intervals, including those related to supply chain management, should be prioritized to achieve the expected benefits of DSD models and minimize COVID-19 risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for the study was provided by the Bill & Melinda Gates Foundation through OPP1192640 to Boston University. The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study protocol was approved by ERES Converge IRB (Zambia), protocol number 2019-Sep-030, the Human Research Ethics Committee (Medical) of the University of Witwatersrand, protocol number M190453, and the Boston University IRB H-38823.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data were obtained from Zambia's national electronic medical record system. Derived data supporting the findings of this study are available from the corresponding author [BEN] on request.ARTAntiretroviral therapyCAGCommunity adherence groupDSDDifferentiated service deliveryHIVHuman immunodeficiency virusMMDMulti-month dispensing